FY2026 EPS Estimates for MediciNova Lowered by HC Wainwright

Key Points

• HC Wainwright lowered MediciNova’s FY2026 EPS estimate to a loss of $0.28 per share from a previous forecasted loss of $0.26, below the current consensus estimate of a $0.26 loss.
• Analyst sentiment remains mixed but leans positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $8.33; individual ratings range from Strong Buy to Sell.
• MediciNova reported a quarterly loss of $0.05 per share, beating estimates by $0.01, while revenue of $0.46 million exceeded the $0.07 million consensus forecast. The stock opened at $1.32 and has a market capitalization of roughly $65 million.

MediciNova, Inc. (NASDAQ:MNOV - Free Report) - Investment analysts at HC Wainwright decreased their FY2026 earnings estimates for shares of MediciNova in a report issued on Friday, August 14th. HC Wainwright analyst L. Egana-Gorrono now forecasts that the biopharmaceutical company will earn ($0.28) per share for the year, down from their prior estimate of ($0.26). The consensus estimate for MediciNova's current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for MediciNova's Q4 2026 earnings at ($0.11) EPS and FY2027 earnings at ($0.45) EPS.

A number of other equities analysts have also recently issued reports on MNOV. Weiss Ratings cut shares of MediciNova from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 11th. D. Boral Capital reissued a "buy" rating and issued a $9.00 price target on shares of MediciNova in a research note on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $8.33.

MediciNova Price Performance

MNOV opened at $1.32 on Tuesday. The firm has a 50 day simple moving average of $1.34 and a 200 day simple moving average of $1.41. MediciNova has a fifty-two week low of $1.17 and a fifty-two week high of $1.96. The company has a market cap of $64.97 million, a price-to-earnings ratio of -6.29 and a beta of 0.63.

MediciNova (NASDAQ:MNOV - Get Free Report) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. MediciNova had a negative net margin of 1,168.70% and a negative return on equity of 26.51%. The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.07 million.

Institutional Trading of MediciNova

A number of institutional investors and hedge funds have recently modified their holdings of the stock. StoneX Group Inc. acquired a new stake in shares of MediciNova in the 4th quarter valued at approximately $25,000. Goldman Sachs Group Inc. acquired a new position in MediciNova during the fourth quarter valued at approximately $35,000. Citadel Advisors LLC bought a new stake in MediciNova in the third quarter valued at approximately $92,000. Bank of New York Mellon Corp bought a new stake in MediciNova in the second quarter valued at approximately $103,000. Finally, Jane Street Group LLC bought a new stake in MediciNova in the fourth quarter valued at approximately $214,000. 9.90% of the stock is owned by institutional investors.

MediciNova Company Profile

MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company's leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source